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Abstract
Background: Cyclin A1 is essential for male gametopoiesis. In acute myeloid leukemia, it acts as a leukemia-associated
antigen. Cyclin A1 expression has been reported in several epithelial malignancies, including testicular, endometrial,
and epithelial ovarian cancer (EOC). We analyzed Cyclin A1 expression in EOC and its correlation with clinical features
to evaluate Cyclin A1 as a T-cell target in EOC.
Methods: Cyclin A1 mRNA expression in EOC and healthy tissues was quantified by microarray analysis and
quantitative real-time PCR (qRT-PCR). Protein expression in clinical samples was assessed by immunohistochemistry
(IHC) and was correlated to clinical features.
Results: Cyclin A1 protein was homogeneously expressed in 43 of 62 grade 3 tumor samples and in 1 of 10
grade 2 specimens (p < 0.001). Survival analysis showed longer time to progression (TTP) among patients with
at least moderate Cyclin A1 expression (univariate: p = 0.018, multivariate: p = 0.035). FIGO stage, grading, age,
macroscopic residual tumor after debulking, and peritoneal carcinomatosis / distant metastasis had no impact
on TTP or overall survival (OS).
Conclusion: Cyclin A1 is highly expressed in most EOCs. The mechanism behind the prolonged TTP in patients with
high Cyclin A1 expression warrants further investigation. The frequent, selectively high expression of Cyclin A1 in EOC
makes it a promising target for T-cell therapies.
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Background
Epithelial ovarian cancer (EOC) is the seventh most
common cancer and the eight most common cause of
cancer-related death among women worldwide [1], with
high-grade serous carcinoma being the most common
histology [2]. About two-thirds of patients with EOC are
diagnosed at an advanced stage with peritoneal or vis-
ceral spread [3]. Standard treatment in that setting is
cytoreductive surgery followed by chemotherapy with
platinum and paclitaxel. Despite high response rates to
first-line systemic treatment, all patients with initially
advanced or secondary metastatic disease relapse, de-
velop platinum resistance, and eventually die from the
disease [4]. Recently, systemic treatment was improved
by the addition of new agents (e.g., bevacizumab and
PARP inhibitors) to the classical cytostatic therapy.
Nevertheless, there is still an unmet need for therapeutic
modalities that can contribute to more sustainable
tumor control without constant exposure to treatment-
related toxicity.
Targeted T-cell therapy consisting of vaccination or
the adoptive transfer of T-cells against defined tumor-
associated antigens (TAA) is a reasonable extension of
established treatment strategies.
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EOCs are immunogenic tumors with spontaneous T-cell
responses in more than 50 % of patients [5–7]. While the
presence of tumor-infiltrating intraepithelial lymphocytes
is associated with prolonged progression-free survival
(PFS) and overall survival (OS), immune evasive factors,
such as the expansion of regulatory T-cells or the expres-
sion of PD-L1 and endothelin B receptor, correlate with
poor survival [8, 9]. Patients with advanced stage EOC
after initial debulking and cytostatic treatment are ex-
cellent candidates for targeted T-cell therapy because
of their minimal tumor burden and tumor immuno-
genicity, which may be enhanced by previous pacli-
taxel treatment [5–7].
One essential step in the development of a T-cell
based therapy is the choice of an appropriate antigen
[10, 11]. Besides the so-called neoantigens, which are
generated by somatic mutations in the neoplastic cells
(e.g., p53) and are usually patient-specific, the targetable
TAAs in EOC are usually self-antigens, which are non-
mutated proteins aberrantly expressed by the tumor.
More than 20 self-antigens have been described in EOC,
including several membrane-bound proteins with limited
processing and presentation (e.g., ERBB2, MUC16, and
Mesothelin) [12] and others that are significantly
expressed in normal tissue (e.g., Mesothelin, Cyclin I,
FOLR1, WT1, and MUC1)., implying not only tolerance
by the peripheral T-cell repertoire, but also the risk of
immunogenic toxicity (on-target/off-tumor toxicity) in
the case of an effective T-cell response. The expression
of some TAAs is irrelevant for the maintenance of the
malignant phenotype, with unstable expression in the
malignant cells (e.g., MUC16). Further, some TAAs are
only expressed in a small percentage of patients (e.g.,
ERBB2), are heterogeneously expressed (e.g., NY-ESO-1),
or are expressed in the activated T-cells (e.g., Survivin,
hTERT) [13-18]. Therefore, the identification of new
TAAs with stable, homogeneous, and selective expres-
sion in EOC is an urgent need for the development of
T-cell-based therapies for EOC.
We recently described Cyclin A1 as a T-cell antigen
with aberrant expression in the stem cell compartment
of acute myeloid leukemia [19]. In healthy individuals,
Cyclin A1 expression is restricted to the testis, where it
plays a crucial role in meiosis I of gametopoiesis. The
highly selective expression pattern has not only been
shown at the mRNA and protein level, but also by ligan-
dome analysis, demonstrating that Cyclin A1 peptides
bind to MHC class I in acute myeloid leukemia cells but
not in healthy tissues or during normal hematopoiesis
[10, 19]. Cyclin A1 proved to be immunogenic in vitro,
and several MHC class I epitopes have been described.
In an in silico analysis of Cyclin A1 expression in solid
tumors, we found high Cyclin A1 expression in all four
specimens analyzed. Currently, we have only sparse data
on the impact of Cyclin A1 on proliferation, invasive-
ness, and resistance to apoptosis in EOC [20]. Further-
more, the potential prognostic impact of Cyclin A1
expression in EOC has not yet been addressed.
The aim of this study was to analyze Cyclin A1 expres-
sion at both the mRNA level and the protein level with
regard to the potential use of Cyclin A1 as a T-cell anti-
gen in EOC. Furthermore, correlations with histopatho-
logical and clinical features were performed to




Microarray data sets were obtained from the NCBI GEO
database. For qRT-PCR and IHC, 72 patients were se-
lected from the ‘Tumor Bank Ovarian Cancer Network’
database based on histology and initial treatment. The
tumor specimens were collected before the onset of the
chemotherapy. All patients suffered from serous EOC
and received cytoreductive surgery followed by
platinum-based chemotherapy. Patients provided written
informed consent for use of their biomaterial samples in
biomarker studies. Consent was obtained using the stan-
dardized informed consent forms of the participating in-
stitutions. The project and consent process was
approved by the ethic board of the Charité Hospital,
Berlin (reference number EA2/005/14).
Microarray data analysis
To further determine the frequency of Cyclin A1 expres-
sion in EOC, 20 tumor samples (GSE14001) were ana-
lyzed along with healthy tissues (GSE3526). The samples
were normalized using the invariant set method (dChip
2.0 software) [21]. Samples exceeding the mean expres-
sion level plus three standard deviations of the healthy,
non-testicular tissue samples were considered positive
(Additional file 1).
Quantitative real-time PCR
Total RNA was extracted from cells and frozen tissue
using Trizol reagent (Invitrogen, Carlsbad, California,
USA) and from paraffin-embedded samples using the
RNeasy FFPE kit (Qiagen,Venlo, Niederlande). The RNA
was reverse transcribed using Superscript III (Invitro-
gen). Complementary DNA from healthy tissues was ob-
tained from Clontech (Mountain View, CA, USA).
Quantitative real-time PCR (qRT-PCR) was performed
on a Light Cycler instrument (Roche, Basel, Switzerland)
with an annealing temperature of 60 °C using previously
published primers and probes [19]. Crossing points were
plotted against the standard curves of pCR4-TOPO plas-
mids (Invitrogen) containing the respective PCR prod-
ucts. All reactions were performed in duplicate.
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Expression levels were presented as copies of Cyclin A1
per copies of the housekeeping gene GAPDH. Samples
exceeding the mean expression level plus three standard
deviations of the samples of healthy tissues were consid-
ered positive.
Immunohistochemistry staining
Tumor specimens were cut in 4-μm-thick sections and
mounted on glass slides. After paraffin removal, hydra-
tion, heat-activated antigen retrieval in the DAKO-PT-
link module (DAKO Glostrup, Denmark), and blocking
of endogenous peroxidase activity by exposure to 3 %
hydrogen peroxide for 20 min, the slides were incubated
at 4 °C overnight with mouse anti-Cyclin A1 monoclonal
antibody, clone 722407 (R&D Systems, Abingdon, UK)
at a 1:25 dilution. After washing, the sections were proc-
essed with a Polymer HRP detection system (PV-9000,
Zhongsam Company, Beijing, China). The slides were
than stained with 3,3′-Diaminobenzidine and counter-
stained in hematoxylin. The staining intensity and the
percentage of positive cells were evaluated at 400× mag-
nification without knowledge of clinical data.
Only cells with nuclear Cyclin A1 staining were con-
sidered positive. The staining intensities were expressed
as weak (1), weak to moderate (1.5), moderate (2), mod-
erate to strong (2.5), or strong (3). The evaluation was
performed by an experienced gynecopathologist (RA).
Statistics
A non-parametric correlation analysis was performed by
calculating Spearman’s ρ. Expression values were com-
pared using a two-tailed Mann–Whitney test or a
Kruskal-Wallis test. TTP and OS were calculated from
the time of initial surgery. Survival analysis was per-
formed using a log-rank test. A multivariate survival
analysis was performed using Cox regression. Statistical
analyses were conducted using SPSS 19 statistical soft-
ware (SPSS Inc., Chicago, IL, USA).
Results
Patients
Cyclin A1 expression was analyzed immunohistochemi-
cally in tumor material from 72 patients primarily with
advanced EOC who underwent cytoreductive surgery
followed by platinum-based chemotherapy (carboplati-
num/paclitaxel in 71 patients, cisplatinum/paclitaxel in
one patient). The mean age of the patients was 59
(range: 37 to 78) years. Further patient characteristics
are given in Table 1.
Cyclin A1 is homogenously expressed in most high-grade
epithelial ovarian cancers
To identify tumor entities with frequent aberrant Cyc-
lin A1 expression, a microarray panel from the NCBI
GEO data base (GEO, http://www.ncbi.nlm.nih.gov/
geo/) containing healthy tissues and samples of 21
tumor entities was screened. Probe set 205899_at,
which represents Cyclin A1 on the respective micro-
array platform, and which has been validated in earl-
ier studies, was analyzed [19].
The panel contained four EOC samples, which all
showed significant overexpression of Cyclin A1 com-
pared to healthy tissues (data not shown).
Next, a microarray containing a panel of 20 EOC spec-
imens was analyzed and revealed Cyclin A1 expression
in all ten high-grade samples and in five of the ten low-
grade samples (GSE14001, GSE3526, Fig. 1). To further
validate the in silico findings, Cyclin A1 was quantified
by qRT-PCR in eight snap-frozen EOC specimens and in
a variety of healthy tissues. Again, there was no Cyclin
A1 expression in healthy tissues except for the testis, but
seven of the nine EOC specimens tested positive for
Cyclin A1 mRNA (Fig. 2).
Cyclin A1 was then analyzed at the protein level to
confirm proper translation and to detect potential het-
erogeneity of expression within the tumors. To validate
the immunohistochemical staining, RNA was extracted
from paraffin-embedded slides of nine samples, and
qRT-PCR was performed. There was a significant correl-
ation between staining intensity and Cyclin A1 mRNA
expression (ρ = 0.685, p = 0.042, data not shown), con-
firming the specificity of the immunohistochemical
staining. Representative images of varying staining


















*Platinum sensitivity is defined as relapse-free survival for at least six months
after the end of initial platinum-based chemotherapy




























































































































































































Fig. 1 Microarray data showing high Cyclin A1 expression in high-grade and low-grade serous ovarian carcinoma and testis relative to
other tissues. Graph shows model-based expression of probe set 205889_at, representing Cyclin A1. LGOC, low-grade ovarian cancer;
























































































































Fig. 2 qRT-PCR of snap-frozen EOC specimens and of cDNA from healthy tissues, showing high Cyclin A1 expression in testis and seven of the nine
EOCs. Graph shows expression of Cyclin A1 (copies/copies of GAPDH) in relation to expression in testis (=100 %). Mean value + 3SD is marked by the
horizontal bar
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intensities are shown in Fig. 3. There was a strong correl-
ation between the staining intensity and the percentage of
positive cells in all 72 patients (ρ = 0.436, p = 0.0001, data
not shown). Homogenous Cyclin A1 positivity was ob-
served in 43 of 62 grade 3 specimens, but in only 1 of 10
grade 2 specimens (p = 0.005, Fig. 4). The percentage of
positive cells, but not staining intensity, was significantly
higher in the grade 3 specimens (p < 0.001; p = 0.394)
(Fig. 5 A,B).
Cyclin A1 expression is associated with prolonged time to
progression
Cyclin A1 expression in all 72 patients was then corre-
lated to the clinical features to identify a potential prog-
nostic relevance of Cyclin A1 in EOC. Median TTP and
OS of all patients were 19.0 months (range 7.7 to 85.7)
and 46.0 months (8.6 to 85.7), respectively. There were
no statistically significant differences in either the inten-
sity of Cyclin A1 staining or the percentage of Cyclin
A1-positive cells in regard to the clinical stage, the age
at first diagnosis, or presentation with peritoneal carcin-
omatosis / distant metastasis or platinum sensitivity
(Fig. 5 C-F and data not shown). However, high Cyclin
A1 expression (Cyclin A1high) was associated with pro-
longed TTP in an univariate survival analysis (p = 0.018,
27.5 vs. 14.6 months) (Fig. 6, Additional file 2: Table S1).
To rule out a potential bias from different efficacies in
surgical cytoreduction, a second analysis was performed
including only patients with residual macroscopic tumor
(n = 20). In that population, the difference in TTP be-
tween Cyclin A1high and Cyclin A1low patients was even
greater (median TTP 26.1 vs. 13.0 months), suggesting
that Cyclin A1 expression is predictive of patient respon-
siveness to the standard fist-line chemotherapy regimen
(Fig. 7).
To further confirm that observation, we used the
online-accessible tool ‘Kaplan-Meier-Plotter’ [22] to
analyze data from six independent studies and ‘The Can-
cer Genome Atlas’ (TCGA, version 2011). Altogether,
264 cases with serous EOC stage II to IV, suboptimal
debulking, and platinum-containing treatment were se-
lected. Again, higher Cyclin A1 expression levels were
associated with longer TTP (p = 0.0088, Additional file 3:
Figure S1), while no statistical difference in TTP could
be observed in the cohort of patients with optimally
debulked EOC (data not shown).
We then conducted a multivariate analysis of TTP in-
cluding the four covariates with the lowest p-values in the
univariate analysis: Cyclin A1 staining intensity, the per-
centage of Cyclin A1-positive cells, FIGO stage, and peri-
toneal carcinomatosis. Only Cyclin A1high staining
intensity was an independent indicator for prolonged TTP
(p = 0.035) (Additional file 2: Table S1). Furthermore,
while homogeneous positivity for Cyclin A1 was associ-
ated with longer OS in the univariate analysis (p = 0.044,
65.3 vs. 42.2 months) (Fig. 6D), none of the parameters
were independent prognostic markers for OS (Additional
file 2: Table S1).
Fig. 3 Immunohistochemistry for Cyclin A1. a Positive control testis. b–d Representative immunohistochemical staining in serous carcinoma of
the ovary: B-weak staining intensity; C-moderate staining intensity; D-strong staining intensity. Original magnification 20 × 10
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The impact of Cyclin A1 expression on TTP is not
associated with cancer molecular subtypes
Recently, four molecular subgroups of high-grade ovarian
cancer [C1 (high stromal response), C2 (high immune sig-
nature), C4 (low stromal response), and C5 (mesenchy-
mal)] have been described based on microarray data [23].
The most common subtype, C1, is characterized by
shorter progression-free survival after initial treatment
compared with the other subtypes. To test whether a low
Cyclin A1 level could be a surrogate marker for the C1
subtype rather than an independent prognostic factor, the
original microarray data was analyzed for Cyclin A1 ex-
pression (probe set 205889_at, Additional file 4: Figure
S2). Cyclin A1 expression was significantly different
among the four subtypes (p = 0.001), with C1 showing the
highest expression and C5 showing the lowest expression.
If Cyclin A1 was a pure surrogate marker for C1, we
would have expected a lower expression in C1 in relation
to other subtypes. Even though the comparison of our
data with mRNA data from a second independent cohort
has limited informative value, this observation implies that
the impact of Cyclin A1 expression on TTP is not directly
associated with the molecular subtype.
Discussion
Here, we provided the first linear mRNA expression ana-
lysis of Cyclin A1 in EOC and healthy tissuesand put im-
munohistochemical Cyclin A1 expression into a clinical
context. We showed that Cyclin A1 is highly and homo-
geneously expressed in high-grade EOC in a high per-
centage of patients. Furthermore, we identified Cyclin







grade 2 grade 3
Fig. 4 Immunohistochemical Cyclin A1 expression features (staining intensity and percentage of positive cells) of all 72 specimens analyzed
depending on histopathological grade. Homogenous positivity (shaded in red) in 43 of 62 grade 3 specimens, but in only one grade 2 specimen













































































Fig. 5 Comparison of staining intensities (b,d,f) and percentage of positive cells (a,c,e) depending on histopathological grading (a,b), FIGO stage
(c,d), and platinum responsiveness (e,f). * indicates significant differences (non-parametric). Median values are marked by horizontal bars
Arsenic et al. BMC Cancer  (2015) 15:784 Page 6 of 11
based first-line chemotherapy, independent of other clin-
ical features, histological grading, and molecular
subtype.
The identification of an appropriate antigen that is se-
lectively overexpressed in a given tumor entity is a crit-
ical step in the development of a T-cell-based treatment.
We pursued a reverse strategy by first selecting the
testis-selective antigen Cyclin A1 [19] and then screen-
ing its expression in a multitude of different non-
hematological tumor entities. In the initial in silico
screening, only EOC showed high Cyclin A1 expression
in all data sets analyzed. Cyclin A1 overexpression has
already been described in a small set of EOC samples as
well as in testicular germ cell tumors and endometrial
cancer [24]. We decided to pursue Cyclin A1 as a poten-
tial T-cell target in EOC for several reasons. First, EOC
is considered an immunogenic tumor with T-cell infiltra-
tion being associated with better prognosis [6, 8].
Second, initial exposure to paclitaxel seems to enhance
the presentation of TAA epitopes by the malignant cells
[25, 26] Furthermore, the clinical course of EOC is usu-
ally characterized by effective initial tumor reduction by
Fig. 6 a Difference in time to progression after surgery in relation to staining intensity: blue-Cyclin A1low; green-Cyclin A1high (p = 0.018). b Difference
in overall survival after surgery in relation to staining intensity: blue-Cyclin A1low; green-Cyclin A1high (p = 0.155). c Difference in time to progression
after surgery in relation to percentage of cells: blue- < 100 % of cells; green-100 % of cells (p = 0.253). d Difference in overall survival after surgery in
relation to percentage of cells: blue- < 100 % of cells; green-100 % of cells (p = 0.044). The time is given in months
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surgery and systemic treatment, followed by an interval
without cytostatic therapy and minimal tumor burden, a
clinical setting which is considered an ideal condition
for immunotherapeutic intervention.
A National Cancer Institute pilot project to prioritize
cancer antigens developed a list of weighted “ideal” anti-
gen criteria/characteristics, which can be used to evalu-
ate new tumor antigen candidates. The absence of
relevant expression in healthy tissues with the exception
of testis, which is considered to be an immunoprivileged
site, is one of the central features of a T-cell antigen be-
cause of potential on-target/off-tumor toxicities when
the antigen is expressed in healthy tissues. This selective
oncofetal expression pattern was demonstrated for Cyc-
lin A1 in a previous study [19]. Other criteria, which are
not specific to the targeted tumor entity and apply to
Cyclin A1, are an intracellular location and a high num-
ber of available epitopes. Furthermore, high expression
in the tumor in a large fraction of patients is essential.
In the larger set of ovarian cancer samples, we detected
Cyclin A1 staining in all the samples, with at least mod-
erate staining in half of the samples irrespective of the
histological grade. This high frequency of antigen posi-
tivity promises easy patient accrual for potential clinical
trials and would guarantee broad applicability if Cyclin
A1 can be effectively targeted in a clinical setting. An-
other feature of a suitable antigen is a high frequency of
positive cells within the tumor tissue [27]. Cyclin A1 ful-
fills this criterion, being homogenously expressed at a
moderate to high level in more than half of the high-
grade carcinomas analyzed. Our mRNA and protein
expression data are complemented by the results of a
large human leukocyte antigen (HLA)-ligandome study
showing Cyclin A1 peptide presentation in the context
of MHC class I in ovarian cancer but not in healthy tis-
sues or hematopoiesis (Heiko Schuster, Tübingen, per-
sonal communication), making Cyclin A1 an attractive
T-cell target in patients with EOC.
The function of Cyclin A1 in normal and malignant
somatic cells is only partially understood and might de-
pend on the expression level, differentiation grade, and
tissue of origin. Cyclin A1 expression enhances G1/S
transition in somatic cells and is associated with en-
hanced proliferation and invasiveness in cancers of the
breast, prostate, urothelium, and thyroid [28-32]. At the
same time, the induction of apoptosis by both intrinsic
and extrinsic pathways increases the Cyclin A1 protein
level by both p53-mediated transcription and post-
translational modification. Moreover, Cyclin A1 seems
to enhance the pro-apoptotic effect of p53 [20, 33], and
the Cyclin A1/CDK2-mediated phosphorylation of p53
enables stable complex formation with topoisomerase I,
thereby causing hyper-recombination in p53 mutant
cells [34]. Although the data on EOC are very limited,
this mechanism might play a significant role in oncogen-
esis in EOC, given that Cyclin A1 expression was uni-
formly high in the ovarian cancer samples, and both p53
mutations and genomic instability are characteristic fea-
tures of EOC [35, 36].
We identified Cyclin A1 expression as a predictive
marker for longer TTP after first-line cytostatic treat-
ment in two independent data sets, one based on protein
Fig. 7 a Difference in time to progression after surgery in relation to staining intensity by the patients without macroscopic residual
tumor: blue-Cyclin A1low green-Cyclin A1high (p = 0.018). b Difference in time to progression after surgery in relation to staining intensity
by the patients with macroscopic residual tumor: blue-Cyclin A1low; green-Cyclin A1high (p = 0.031)
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expression and one based on mRNA levels [22]. This ef-
fect was independent of the disease stage at first diagno-
sis, peritoneal carcinomatosis, histological grade and age,
and was stronger in patients with suboptimal surgical
cytoreduction. The longer TTP in patients with higher
Cyclin A1 levels might therefore reflect responsiveness
to cytostatic treatment rather than an association be-
tween more aggressive tumor biology and later-stage dis-
ease at first diagnosis. Cyclin A1 directly interacts not
only with p53 but also with at least two members of the
Retinoblastoma gene product (pRB) pathway, pRB and
E2F-1, which regulates proliferation and is itself modu-
lated by p53 [37]. Several molecules in that complex net-
work (p53, p21, pRb, and E2F-1) have been discussed as
predictive markers for treatment response or prognosis
in EOC [38-41].
It remains unclear whether Cyclin A1 expression is a
surrogate marker for dysregulation of the pRB-p53 net-
work or whether its own anti-apoptotic effect or modu-
lation of the pRB pathway substantially contributes to
the longer TTP. p53 is mutated and believed to be tran-
scriptionally defective in the majority of patients. No dif-
ference in Cyclin A1 expression could be detected
between EOC with wild type p53 and with mutated p53
[42]. This, and the fact that several oncogenes have been
identified as Cyclin A1 transcription factors in malignant
cells [43, 44], makes a direct Cyclin A1-mediated effect
seem more likely.
Gene expression profiling for class discovery has been
widely applied to ovarian cancer. The definition of four
distinct molecular subtypes of EOC by Tothill et al. has
found broad acceptance due to its biological consistency
and clinical relevance. Compared with the other sub-
types, subtype C1 (high stromal response) has a signifi-
cantly shorter TTP [23]. To determine whether Cyclin
A1 is expressed differentially in the different subgroups,
and more specifically, whether a low Cyclin A1 level
might be a surrogate marker for the C1 subtype, we
compared Cyclin A1 expression among the different
subtypes. Cyclin A1 expression was indeed significantly
different between the four subtypes, but with expression
in C1 significantly higher compared with the other sub-
types. When evaluating self-proteins as potential T-cell
targets, the actual translation of the protein is a pivotal
factor. Consequently, we analyzed our clinical samples
with IHC. On the other hand, the assignment to a mo-
lecular subtype requires the mRNA expression data of a
microarray. Because microarray data of the clinical sam-
ples was not available, and Tothill et al. did not provide
protein data for Cyclin A1, a direct comparison between
the two factors (cluster analysis by microarray and pro-
tein expression) was not possible. Despite these limita-
tions, and given that C1 is characterized by short TTP,
its association with high Cyclin A1 expression on mRNA
level implies that Cyclin A1 is not a pure surrogate
maker for C1, and its impact on TTP might be at least
partially independent of the molecular subtype.
Conclusions
Cyclin A1 appears to be a highly suitable antigen in pa-
tients with EOC for targeted T-cell therapy because of
its selectively high expression in the vast majority of
high-grade ovarian cancers irrespective of clinical stage.
In view of its predescribed immunological features and
expression pattern in EOC, Cyclin A1 should be pursued
further as a T-cell target for an application in a clinical
setting. Independent of its potential role as a target for
T-cell therapy, Cyclin A1 acts as predictive marker for
response to standard platinum-based cytostatic therapy,
translating into prolonged TTP. This, its differential ex-
pression in the molecular subtypes, and the already
known interactions with other cell cycle regulating genes
indicate a clinically relevant pathophysiological function
for Cyclin A1 in EOC, which remains to be further
elucidated.
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Additional file 3: Figure S1. Survival plot depicting the impact of Cyclin
A1 expression (Affymetrix probe set 205899_at) on progression-free survival
in the patient group with suboptimal debulking and platinum-based
therapy using an online-accessible tool (www.kmplot.com/), database ver-
sion 2015 [n = 1648]. Case selection [n = 264]: survival: PFS, split patients by
median; restrictions: FIGO II, III, IV; histology: serous; debulk: suboptimal;
chemotherapy: contains platinum. Log-rank p = 0.0088. (PPTX 84 kb)
Additional file 4: Figure S2. Differences in Cyclin A1 expression between
molecular tumor subtypes (1, 2, 4, and 5), according to the molecular
classification of EOC by Tothill et al. Data sets were retrieved from the NCBI
GEO database and normalized using the invariant set method (dChip 2.0
software) [23]. C1 showed significantly higher expression and C5 showed
significantly lower expression (Kruskall Wallis; p = 0.001). Mean value + 3SD is
marked by the horizontal bar. (PPT 147 kb)
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